Paper40484646
Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancer.
Guo X and 13 others. J Immunother Cancer, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancer. Papers, record 40484646. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40484646
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancer.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colorectal Neoplasms | Major topic |
| Oncolytic Virotherapy | Major topic |
| Killer Cells, Natural | Major topic |
| Protein Serine-Threonine Kinases | Major topic |
| Intercellular Adhesion Molecule-1 | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Oncolytic Viruses | Major topic |
| Humans | |
| Animals | |
| Mice | |
| Cell Line, Tumor | |
| Female |
Source PubMed
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36634707 | Targeting TBK1 to overcome resistance to cancer immunotherapy. | Nature | 2023 | https://conductscience.org/library/papers/36634707 | PubMed |
| 2 | 38750019 | Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways. | Nat Commun | 2024 | https://conductscience.org/library/papers/38750019 | PubMed |
| 3 | 27049944 | The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. | Nature | 2016 | https://conductscience.org/library/papers/27049944 | PubMed |
| 4 | 36864254 | Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer. | Nat Med | 2023 | https://conductscience.org/library/papers/36864254 | PubMed |
| 5 | 34747156 | An Inter-Supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer. | Adv Sci (Weinh) | 2022 | https://conductscience.org/library/papers/34747156 | PubMed |
| 6 | 38167409 | Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma. | Nat Commun | 2024 | https://conductscience.org/library/papers/38167409 | PubMed |
| 7 | 38693119 | Fn-OMV potentiates ZBP1-mediated PANoptosis triggered by oncolytic HSV-1 to fuel antitumor immunity. | Nat Commun | 2024 | https://conductscience.org/library/papers/38693119 | PubMed |
| 8 | 37267951 | Methionine restriction promotes cGAS activation and chromatin untethering through demethylation to enhance antitumor immunity. | Cancer Cell | 2023 | https://conductscience.org/library/papers/37267951 | PubMed |
| 9 | 38519366 | Emerging roles of TBK1 in cancer immunobiology. | Trends Cancer | 2024 | https://conductscience.org/library/papers/38519366 | PubMed |
| 10 | 17018283 | RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. | Cell | 2006 | https://conductscience.org/library/papers/17018283 | PubMed |
| 11 | 22781695 | Oncolytic virotherapy. | Nat Biotechnol | 2012 | https://conductscience.org/library/papers/22781695 | PubMed |
| 12 | 30210920 | Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. | Am J Cancer Res | 2018 | https://conductscience.org/library/papers/30210920 | PubMed |
| 13 | 34117484 | Natural killer cells in antiviral immunity. | Nat Rev Immunol | 2022 | https://conductscience.org/library/papers/34117484 | PubMed |
| 14 | 36385525 | Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation. | Nature | 2022 | https://conductscience.org/library/papers/36385525 | PubMed |
| 15 | 36765091 | Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. | Nat Commun | 2023 | https://conductscience.org/library/papers/36765091 | PubMed |
| 16 | 31792381 | TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis. | Nat Cell Biol | 2019 | https://conductscience.org/library/papers/31792381 | PubMed |
| 17 | 38909621 | Colorectal cancer. | Lancet | 2024 | https://conductscience.org/library/papers/38909621 | PubMed |
| 18 | 38211588 | Kinome-wide siRNA screen identifies a DCLK2-TBK1 oncogenic signaling axis in clear cell renal cell carcinoma. | Mol Cell | 2024 | https://conductscience.org/library/papers/38211588 | PubMed |
| 19 | 37989995 | PTK2B promotes TBK1 and STING oligomerization and enhances the STING-TBK1 signaling. | Nat Commun | 2023 | https://conductscience.org/library/papers/37989995 | PubMed |
| 20 | 35792620 | CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma. | Cancer Res | 2022 | https://conductscience.org/library/papers/35792620 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42378815 | Mechanisms and advances of drug resistance in colorectal cancer: A systematic overview of multi-layered regulatory networks. | Transl Oncol | 2026 | https://conductscience.org/library/papers/42378815 | PubMed |
| 41923622 | Engineered oncolytic virus armed with anti-PCSK9 scFv boosts long-term CD8+ T cell immunity via rewiring MHC-I antigen presentation. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/41923622 | PubMed |
| 41440025 | Oncolytic Virotherapy in Colorectal Cancer: Mechanistic Insights, Enhancer Strategies, and Translational Combinations. | Cells | 2025 | https://conductscience.org/library/papers/41440025 | PubMed |
| 41416429 | Advancements on the synergistic application of oncolytic viruses and molecularly targeted therapies for the treatment of solid tumors (Review). | Int J Oncol | 2026 | https://conductscience.org/library/papers/41416429 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ICAM1 | 3383 | PubTator's text mining | https://conductscience.org/library/genes/3383 | NCBI Gene |
| RIPK1 | 8737 | PubTator's text mining | https://conductscience.org/library/genes/8737 | NCBI Gene |
| TBK1 | 29110 | PubTator's text mining | https://conductscience.org/library/genes/29110 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40484646
GET https://conductscience.org/api/papers/v1/40484646/references?page=2